Thrombospondin-2 therapy ameliorates experimental glomerulonephritis via inhibition of cell proliferation, inflammation, and TGF-β activation

American Journal of Physiology - Renal Physiology

Volumn 297, Issue 5, 2009, Pages

  Daniel, Christoph ^a   Wagner, Andrea ^a   Hohenstein, Bernd ^b   Hugo, Christian ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Extracellular matrix; Glomerulonephritis; Proliferation; Thrombospondin 2; Transforming growth factor activation

Indexed keywords

BETA GALACTOSIDASE; COLLAGEN TYPE 4; PLASMID DNA; THROMBOSPONDIN 2; TRANSFORMING GROWTH FACTOR BETA;

ALLERGIC GLOMERULONEPHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ELECTROPORATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; INFLAMMATION; KIDNEY BIOPSY; KIDNEY FUNCTION; MACROPHAGE MIGRATION; MALE; MESANGIUM CELL; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; RAT;

EID: 70350726351     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00254.2009     Document Type: Article

References (40)

1. Abrass CK. The nature of chronic progressive nephropathy in aging rats. Adv Ren Replace Ther 7: 4-10, 2000.
2. Akagi Y, Isaka Y, Arai M, Kaneko T, Takenaka M, Moriyama T, Kaneda Y, Ando A, Orita Y, Kamada T, Ueda N, Imai E. Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 50: 148-155, 1996. (Pubitemid 26323708)
3. Anders HJ, Vielhauer V, Schlondorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int 63: 401-415, 2003. (Pubitemid 36126787)
4. Armstrong LC, Bjorkblom B, Hankenson KD, Siadak AW, Stiles CE, Bornstein P. Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell 13: 1893-1905, 2002.
5. Bein K, Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 275: 32167-32173, 2000. (Pubitemid 30782107)
6. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360: 361-364, 1992. (Pubitemid 23000677)
7. Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest 107: 929-934, 2001. (Pubitemid 32323400)
8. Cheng S, Pollock AS, Mahimkar R, Olson JL, Lovett DH. Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J 20: 1898-1900, 2006.
9. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 64: 709-727, 1987. (Pubitemid 18047151)
10. Daniel C, Amann K, Hohenstein B, Bornstein P, Hugo C. Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in experimental glomerulonephritis in mice. J Am Soc Nephrol 18: 788-798, 2007. (Pubitemid 46434496)
11. Daniel C, Schaub K, Amann K, Lawler J, Hugo C. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes 56: 2982-2989, 2007. (Pubitemid 350223633)
12. Daniel C, Takabatake Y, Mizui M, Isaka Y, Kawashi H, Rupprecht H, Imai E, Hugo C. Antisense oligonucleotides against thrombospondin-1 inhibit activation of tgf-beta in fibrotic renal disease in the rat in vivo. Am J Pathol 163: 1185-1192, 2003. (Pubitemid 37040154)
13. Daniel C, Wiede J, Krutzsch HC, Ribeiro SM, Roberts DD, Murphy-Ullrich JE, Hugo C. Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int 65: 459-468, 2004. (Pubitemid 38130640)
14. Gagliardini E, Benigni A. Role of anti-TGF-beta antibodies in the treatment of renal injury. Cytokine Growth Factor Rev 17: 89-96, 2006. (Pubitemid 43117518)
15. Gomez-Guerrero C, Hernandez-Vargas P, Lopez-Franco O, Ortiz-Munoz G, Egido J. Mesangial cells and glomerular inflammation: from the pathogenesis to novel therapeutic approaches. Curr Drug Targets Inflamm Allergy 4: 341-351, 2005. (Pubitemid 40873122)
16. Hotchkiss H, Chu TT, Hancock WW, Schroppel B, Kretzler M, Schmid H, Liu Y, Dikman S, Akalin E. Differential expression of profibrotic and growth factors in chronic allograft nephropathy. Transplantation 81: 342-349, 2006. (Pubitemid 43255717)
17. Hugo C, Kang DH, Johnson RJ. Sustained expression of thrombospondin-1 is associated with the development of glomerular and tubulointerstitial fibrosis in the remnant kidney model. Nephron 90: 460-470, 2002. (Pubitemid 34310111)
18. Hugo C, Pichler R, Meek R, Gordon K, Kyriakides T, Floege J, Bornstein P, Couser WG, Johnson RJ. Thrombospondin 1 is expressed by proliferating mesangial cells and is up-regulated by PDGF and bFGF in vivo. Kidney Int 48: 1846-1856, 1995.
19. Hugo C, Shankland SJ, Pichler RH, Couser WG, Johnson RJ. Thrombospondin 1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat. Kidney Int 53: 302-311, 1998. (Pubitemid 28097847)
20. Iruela-Arispe L, Gordon K, Hugo C, Duijvestijn AM, Claffey KP, Reilly M, Couser WG, Alpers CE, Johnson RJ. Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol 147: 1715-1727, 1995.
21. Isenberg JS, Annis DS, Pendrak ML, Ptaszynska M, Frazier WA, Mosher DF, Roberts DD. Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem 284: 1116-1125, 2009.
22. Jacobi J, Porst M, Cordasic N, Namer B, Schmieder RE, Eckardt KU, Hilgers KF. Subtotal nephrectomy impairs ischemia-induced angiogenesis and hindlimb re-perfusion in rats. Kidney Int 69: 2013-2021, 2006. (Pubitemid 43924265)
23. Johnson RJ. The glomerular response to injury: progression or resolution? Kidney Int 45: 1769-1782, 1994.
24. Johnson RJ, Pritzl P, Iida H, Alpers CE. Platelet-complement interactions in mesangial proliferative nephritis in the rat. Am J Pathol 138: 313-321, 1991.
25. Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL, Mazzali M, Jefferson JA, Hughes J, Madsen KM, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 12: 1434-1447, 2001. (Pubitemid 32666326)
26. Keller K, Daniel C, Schocklmann H, Endlich KH, Kerjaschki D, Johnson RJ, Hugo C. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. Nephrol Dial Transplant 21: 2724-2735, 2006. (Pubitemid 44542224)
27. Lange-Asschenfeldt B, Weninger W, Velasco P, Kyriakides TR, von Andrian UH, Bornstein P, Detmar M. Increased and prolonged inflammation and angiogenesis in delayed-type hypersensitivity reactions elicited in the skin of thrombospondin-2-deficient mice. Blood 99: 538-545, 2002. (Pubitemid 34533090)
28. Lawler J, Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 36: 1038-1045, 2004.
29. McGregor B, Colon S, Mutin M, Chignier E, Zech P, McGregor J. Thrombospondin in human glomerulopathies. A marker of inflammation and early fibrosis. Am J Pathol 144: 1281-1287, 1994. (Pubitemid 24172090)
30. McMahon JM, Signori E, Wells KE, Fazio VM, Wells DJ. Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase-increased expression with reduced muscle damage. Gene Ther 8: 1264-1270, 2001. (Pubitemid 32780815)
31. Mizui M, Isaka Y, Takabatake Y, Mizuno S, Nakamura T, Ito T, Imai E, Hori M. Electroporation-mediated HGF gene transfer ameliorated cyclosporine nephrotoxicity. Kidney Int 65: 2041-2053, 2004. (Pubitemid 38669990)
32. Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB. Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int 51: 1376-1382, 1997. (Pubitemid 27239886)
33. Park YW, Kang YM, Butterfield J, Detmar M, Goronzy JJ, Weyand CM. Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. Am J Pathol 165: 2087-2098, 2004. (Pubitemid 39578386)
34. Peters H, Martini S, Wang Y, Shimizu F, Kawachi H, Kramer S, Neumayer HH. Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis. Kidney Int 66: 1434-1443, 2004. (Pubitemid 39298375)
35. Schoecklmann HO, Rupprecht HD, Zauner I, Sterzel RB. TGF-beta1-induced cell cycle arrest in renal mesangial cells involves inhibition of cyclin E-cdk 2 activation and retinoblastoma protein phosphorylation. Kidney Int 51: 1228-1236, 1997. (Pubitemid 27186551)
36. Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD, Murphy-Ullrich JE. Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem 270: 7304-7310, 1995.
37. Tamaki K, Okuda S. Role of TGF-beta in the progression of renal fibrosis. Contrib Nephrol 139: 44-65, 2003.
38. Wittmann S, Daniel C, Braun A, Vogelbacher R, Shimizu F, Kawachi H, Hugo C. The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat. Nephron Exp Nephrol 108: e45-e56, 2008. (Pubitemid 351346991)
39. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199-210, 2008.
40. Yang Z, Strickland DK, Bornstein P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem 276: 8403-8408, 2001. (Pubitemid 37385652)